When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

This collaboration between Eli Lilly and a Top VC fund can redefine how Corporate VC (CVC) fuels innovation – not just in ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

Only a handful of family and friends knew the Brewers' last game of the 2024 season was likely Uecker's last game, too.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...